Navigation Links
Adeona Reports Third Quarter 2011 Financial Results
Date:11/14/2011

lue of the warrants associated with the January 2011 and April 2011 financings, adjusted for the change in their fair value at September 30, 2011. Total net other income for the three months ended September 30, 2011 included $6,868 of interest income from our short-term investments. Other income for the nine months ended September 30, 2011 included $62,996 relating to the settlement of accounts payable previously accrued in prior periods and $6,868 of interest income from our short-term investments.

The net loss for the three months ended September 30, 2011, was $1,097,979 or $0.04 per share compared to $732,835 or $0.03 for the same period in 2010. The net loss for the nine months ended September 30, 2011, was $4,964,336 or $0.18 per share compared to $840,575 or $0.04 per share for the same period in 2010.

As of September 30, 2011, Adeona had approximately $7.5 million in cash, cash equivalents and short-term investments compared to approximately $2.6 million in cash and cash equivalents on December 31, 2010. As of October 31, 2011, we had approximately $7.2 million in cash, cash equivalents and investment in debt securities. Our cash position should allow us to meet our currently planned operating needs for at least the next 12 months.

"During the third quarter of 2011, we achieved several clinical milestones that have positioned us for future growth and expanded the opportunities we believe exist in our core areas of strength," stated James S. Kuo, M.D., M.B.A., Adeona's Chief Executive Officer. "We are currently working on several projects that provide significant opportunities in major areas of medicine, including the recently announced Phase IIb clinical trial for our multiple sclerosis (MS) drug and the Phase IIb clinical trial of our drug for Lou Gehrig's disease (ALS)."

"We also announced in the third quarter the acquisition of exclusive access to two sets of clinical data that demonstrate the safety and efficacy of a particular
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
2. Adeona Senior Vice President of Research & Development to Present at American College of Nutrition Annual Meeting
3. Adeona Appoints Jeff Lucero Riley as Independent Chairman
4. Adeonas Planned Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease is Hot Topic at 2011 California ALS Research Summit
5. Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial
6. Adeona Appoints George A. Eby to Scientific Advisory Board
7. Adeona Reports Second Quarter 2011 Financial Results
8. Adeona to Host Second Quarter 2011 Investor Conference Call
9. Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease (ALS)
10. Adeona Reports 1st Quarter 2011 Financial Results
11. Adeona to Host First Quarter 2011 Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Hologic, Inc. (NASDAQ: ... and Chief Executive Officer, will present at the Morgan Stanley ... , New York on Tuesday, September ... parties are invited to listen to the live audio webcast ... at www.hologic.com/investors-overview . An archive of the presentation will ...
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ ... company committed to the development and commercialization ... today announced an update on corporate and ... structure, commitment for future funding, ongoing clinical ... In corporate news, Chief Executive Officer ...
(Date:9/2/2014)...  BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a ... XIAFLEX ® in the U.S. and XIAPEX ® ... Wegman , will present at the following upcoming investor conferences. ... & Renshaw 16 th Annual Global Investment Conference ... 9, 2014 at 9:10 a.m. EDT , Aegis ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2
... (NASDAQ: AMRI ), a global contract services organization ... as part of its ongoing global operations review to improve ... its European operations focused on a reduction of the workforce ... at its Budapest, Hungary operation. As a ...
... Jan. 9, 2012  Xenon today announced a strategic alliance ... RO, ROG; OTCQX: RHHBY), to discover and develop compounds ... "We are delighted to be collaborating with ... "Genentech is among the world,s leading biotech companies and ...
Cached Medicine Technology:AMRI Announces Review of Its Hungary Operation 2AMRI Announces Review of Its Hungary Operation 3Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics 2
(Date:9/2/2014)... September 02, 2014 The new ... to reduce discomfort and fatigue by absorbing stress and ... eco-friendly, renewable bio-foam core, these anti-fatigue mats are intended ... According to a study by the Texas A&M University, ... difference in reducing spinal compression and increase in sit-reach ...
(Date:9/2/2014)... A little white pill may help scientists learn why ... their peers, even if their lungs are relatively healthy. ... marketed as Revatio to treat pulmonary hypertension and Viagra ... of over-the-counter antioxidants will help them identify the root ... for these patients. , "We want to understand ...
(Date:9/2/2014)... increasing concern to health officials both in NYC and ... Health and Mental Hygiene, the number of unintentional opioid-involved ... of such deaths in 2000. Much of the increase ... prescription opioid (PO) use among teens and young adults, ... transitioned from POs to heroin. , Now researchers ...
(Date:9/2/2014)... new guideline, the Society for Maternal-Fetal Medicine has recommended ... , "There is no evidence that bed rest ... Center for Maternal and Fetal Medicine and one of ... that bed rest can be harmful for moms, babies, ... are placed on bed rest during their pregnancy. Surveys ...
(Date:9/2/2014)... -- Many people believe that marijuana is not addictive, ... more people are able to obtain and consume cannabis ... people are less likely to perceive it as addictive ... Massachusetts General Hospital,s Center for Addiction Medicine, said in ... cannabis use can have significant consequences, and we know ...
Breaking Medicine News(10 mins):Health News:New Eco-Pro Premium Anti-fatigue Mats from Martinson-Nicholls Prevent Fatigue and Discomfort for Standing Workers 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:NYC teens and young adults who abuse prescription at high risk for overdose 2Health News:NYC teens and young adults who abuse prescription at high risk for overdose 3Health News:SMFM releases paper on activity restriction in pregnancy 2Health News:'Pot Addiction' May Be Real, Study Suggests 2
... Intimidation often takes place during the school day, survey ... is often assumed that the schoolyard is where bullies ... study suggests that classrooms are another popular site. ... Health Association,s annual meeting in Philadelphia, is based on ...
... deductibles and offering little gap coverage , FRIDAY, ... standalone Medicare prescription drugs plans (PDP) could encounter significant ... Monthly premiums will rise 11 percent to $38.94, on ... J. Kaiser Family Foundation. That,s up 50 percent from ...
... citizens managing diabetes and vision loss have ... to help them learn how to stay active, eat sensibly and ... expanded AFB Senior Site ( www.afb.org/seniorsite/diabetes ... at Ruth Eckerd Hall in recognition of American Diabetes ...
... that they are similar in many respects to the body,s ... Institutet have found a new way of tackling colon cancer. ... . Molecular signal pathways that stimulate the division of ... tumour growth. This limits the possibility of treating cancer as ...
... - Researchers from Boston University School of Medicine (BUSM) have ... around the heart and the aorta and within the liver, ... appears on-line in Obesity , also found that measuring ... the amount of undesired fat in and around these vital ...
... ... first aid products designed for active lifestyles, today announced its participation at the Silicon ... , ... (PRWEB) November 13, 2009 -- Tender Corp ., a leading manufacturer of over-the-counter ...
Cached Medicine News:Health News:Many Kids Feel Threatened in the Classroom 2Health News:Medicare Part D: What to Expect This Open Enrollment Period 2Health News:Medicare Part D: What to Expect This Open Enrollment Period 3Health News:AFB Senior Site Offers New Information to Help Senior Citizens Manage Diabetes and Vision Loss 2Health News:AFB Senior Site Offers New Information to Help Senior Citizens Manage Diabetes and Vision Loss 3Health News:AFB Senior Site Offers New Information to Help Senior Citizens Manage Diabetes and Vision Loss 4Health News:Paradoxical protein might prevent cancer 2Health News:Fat collections linked to decreased heart function 2Health News:Tender Corp. Announces Participation at Silicon Valley Moms Group's Holiday Coupon Guide & Party 2Health News:Tender Corp. Announces Participation at Silicon Valley Moms Group's Holiday Coupon Guide & Party 3Health News:Tender Corp. Announces Participation at Silicon Valley Moms Group's Holiday Coupon Guide & Party 4Health News:Tender Corp. Announces Participation at Silicon Valley Moms Group's Holiday Coupon Guide & Party 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: